3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
36
Carcinoma, Non-Small-Cell Lung
29
Prostatic Neoplasms
20
Neoplasm Metastasis
19
Breast Neoplasms
19
Colorectal Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
14
Leukemia, Myeloid, Acute
14
Stomach Neoplasms
12
Ovarian Neoplasms
12
Melanoma
12
Lung Neoplasms
12
Carcinoma, Hepatocellular
12
Recurrence
11
Hematologic Neoplasms
10
Endometrial Neoplasms
10
Rectal Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Pancreatic Neoplasms
9
Lymphoma
9
Head and Neck Neoplasms
9
Myasthenia Gravis
8
Leukemia
8
Urinary Bladder Neoplasms
7
Neoplasms by Site
7
Neoplasms by Histologic Type
7
Lymphoma, Large B-Cell, Diffuse
7
Glioblastoma
7
Fatigue
6
Colonic Neoplasms
6
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphatic Abnormalities
×
1 year
×
Clear all
NCT05948943
2026-06-02
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled